Challenges and Strategic Reflections on Taiwan’s Biotechnology Industry

Challenges and Strategic Reflections on Taiwan’s Biotechnology Industry

Amid accelerating deglobalization and intensifying geopolitical tensions, Taiwan’s biotechnology industry confronts structural constraints that limit its strategic positioning within the reconfigured global supply chain. Persistent reliance on a regional market orientation and a fragmented corporate landscape undermines the sector’s ability to compete at higher tiers of global biopharmaceutical competition. The critical question is not whether the external environment has worsened, but whether Taiwan is prepared to upgrade its innovation, commercialization, and governance capabilities.

This study argues that long-term competitiveness depends first on strengthening foundational scientific research to establish technological indispensability. In global supply chain restructuring, technological sovereignty and critical innovation capacity outweigh cost advantages. Without breakthroughs in molecular biology, protein engineering, gene and cell therapy, and other advanced domains, Taiwan risks remaining confined to incremental formulation improvements and downstream manufacturing. Historical cases such as Moderna and BioNTech demonstrate how sustained investment in platform technologies can translate into global leadership during pivotal crises.

Second, Taiwan must transition from traditional contract manufacturing toward high value-added and high-barrier therapeutic areas, including biosimilars, advanced biologics, cell therapy, and regenerative medicine. Competing primarily on scale or cost against established players in South Korea and India would reinforce price-based competition rather than strategic differentiation.

Third, commercialization capability—particularly business development, global licensing, pricing strategy, and market access expertise—must be strengthened to convert scientific innovation into sustainable revenue. Finally, professionalized corporate governance, leadership succession planning, and industry consolidation are essential to achieve economies of scale and enhance bargaining power.

In conclusion, Taiwan’s biotechnology industry must shift from defensive adaptation to strategic upgrading. By integrating foundational innovation, high-value product positioning, global commercialization expertise, governance reform, and industrial consolidation, Taiwan can reposition itself from a peripheral supplier to a critical node in the global biopharmaceutical value chain.